Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of indirect tax technology solutions, reveals that while free, easy product returns are paramount for consumer loyalty, they ...

Vertex Pharmaceuticals trades at $500.94 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 1.6%.

Vertex expects its fourth-quarter 2024 revenues to be in the range of $175-$178 million. The Zacks Consensus Estimate for Vertex’s fourth-quarter 2024 revenues is pegged at $176.6 million ...

According to InvestingPro data, analyst targets for Vertex now range from $330 to $615, reflecting diverse market ...

Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Projected revenue growth for 2025 is expected to range from $760 million to $768 ... company's financial stability amid current losses. Vertex's total revenues for Q4 2024 were $178.5 million ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Learn more about whether Elastic N.V. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which ...

Finally, GRR was 95% in the fourth quarter within our targeted best-in-class range of 94% to 96%. Our 2024 results demonstrate the durability and consistency of Vertex’s business model.